{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:29:21Z","timestamp":1787729361915,"version":"build-2784847793"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL148432"],"award-info":[{"award-number":["HL148432"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R00HL119605"],"award-info":[{"award-number":["R00HL119605"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL140067"],"award-info":[{"award-number":["R01 HL140067"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL151472"],"award-info":[{"award-number":["R01HL151472"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R56HL145034"],"award-info":[{"award-number":["R56HL145034"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Anthracycline antineoplastic agents such as doxorubicin are widely used and highly effective component of adjuvant chemotherapy for breast cancer and curative regimens for lymphomas, leukemias, and sarcomas. The primary dose-limiting adverse effect of anthracyclines is cardiotoxicity that typically manifests as cardiomyopathy and can progress to the potentially fatal clinical syndrome of heart failure. Decades of pre-clinical research have explicated the complex and multifaceted mechanisms of anthracycline-induced cardiotoxicity. It is well-established that oxidative stress contributes to the pathobiology and recent work has elucidated important central roles for direct mitochondrial injury and iron overload. Here we focus instead on emerging aspects of anthracycline-induced cardiotoxicity that may have received less attention in other recent reviews: thrombosis, myocardial atrophy, and non-apoptotic programmed cell death.<\/jats:p>","DOI":"10.3389\/fcvm.2021.817977","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:20:36Z","timestamp":1642378836000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Novel Mechanisms of Anthracycline-Induced Cardiovascular Toxicity: A Focus on Thrombosis, Cardiac Atrophy, and Programmed Cell Death"],"prefix":"10.3389","volume":"8","author":[{"given":"Silvio","family":"Antoniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanya","family":"Phungphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaokang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/0024-3205(81)90001-1","article-title":"Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress","volume":"29","author":"Olson","year":"1981","journal-title":"Life Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1161\/CIRCRESAHA.119.314681","article-title":"Mitochondrial determinants of doxorubicin-induced cardiomyopathy","volume":"126","author":"Wallace","year":"2020","journal-title":"Circ Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","article-title":"Cancer therapy-associated thrombosis","volume":"41","author":"Grover","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B4","first-page":"677","article-title":"Venous thrombosis during multimodal treatment of primary breast carcinoma","volume":"65","author":"Weiss","year":"1981","journal-title":"Cancer Treat Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/1097-0142(19841001)54:7<1264::AID-CNCR2820540706>3.0.CO;2-R","article-title":"Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients","volume":"54","author":"Goodnough","year":"1984","journal-title":"Cancer."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","article-title":"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy","volume":"100","author":"Zangari","year":"2002","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.breast.2010.09.001","article-title":"The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer","volume":"20","author":"Nolan","year":"2011","journal-title":"Breast."},{"key":"B8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1055\/s-0029-1234140","article-title":"The metabolic syndrome as a risk factor for venous and arterial thrombosis","volume":"35","author":"Dentali","year":"2009","journal-title":"Semin Thromb Hemost."},{"key":"B9","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1097\/FJC.0000000000001140","article-title":"Metabolic syndrome: synergistic risks for doxorubicin-induced cardiotoxicity","volume":"78","author":"Gomez-Sanchez","year":"2021","journal-title":"J Cardiovasc Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1200\/JCO.2016.67.4846","article-title":"Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis","volume":"34","author":"Guenancia","year":"2016","journal-title":"J Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"117843","DOI":"10.1016\/j.lfs.2020.117843","article-title":"The role of metabolic diseases in cardiotoxicity associated with cancer therapy: what we know, what we would know","volume":"255","author":"L'Abbate","year":"2020","journal-title":"Life Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11864-020-00812-1","article-title":"Metabolic aspects of anthracycline cardiotoxicity","volume":"22","author":"Russo","year":"2021","journal-title":"Curr Treat Options Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/j.1538-7836.2009.03477.x","article-title":"Doxorubicin-induced platelet cytotoxicity: a new contributory factor for doxorubicin-mediated thrombocytopenia","volume":"7","author":"Kim","year":"2009","journal-title":"J Thromb Haemost."},{"key":"B14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/toxsci\/kfr222","article-title":"Doxorubicin-induced platelet procoagulant activities: an important clue for chemotherapy-associated thrombosis","volume":"124","author":"Kim","year":"2011","journal-title":"Toxicol Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.thromres.2011.06.022","article-title":"Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity","volume":"129","author":"Boles","year":"2012","journal-title":"Thromb Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1538-7836.2009.03300.x","article-title":"Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes","volume":"7","author":"Swystun","year":"2009","journal-title":"J Thromb Haemost."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1161\/01.ATV.0000168421.13467.82","article-title":"Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition","volume":"25","author":"Dahlback","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"35376","DOI":"10.1038\/srep35376","article-title":"Massive release of extracellular vesicles from cancer cells after photodynamic treatment or chemotherapy","volume":"6","author":"Aubertin","year":"2016","journal-title":"Sci Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1158\/1078-0432.CCR-17-2046","article-title":"Extracellular vesicles released by cardiomyocytes in a doxorubicin-induced cardiac injury mouse model contain protein biomarkers of early cardiac injury","volume":"24","author":"Yarana","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.7150\/thno.53637","article-title":"Phosphatidylserine-exposing tumor-derived microparticles exacerbate coagulation and cancer cell transendothelial migration in triple-negative breast cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics."},{"key":"B21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1161\/ATVBAHA.120.315187","article-title":"Oxidative stress product, 4-hydroxy-2-nonenal, induces the release of tissue factor-positive microvesicles from perivascular cells into circulation","volume":"41","author":"Ansari","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1161\/ATVBAHA.120.315437","article-title":"New cellular source of TF (tissue factor)-positive extracellular vesicles in the circulation","volume":"41","author":"Antoniak","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1182\/hematology.2019000025","article-title":"Update from the laboratory: mechanistic studies of pathways of cancer-associated venous thrombosis using mouse models","volume":"2019","author":"Hisada","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/MOH.0000000000000521","article-title":"Cancer cell-derived tissue factor-positive extracellular vesicles: biomarkers of thrombosis and survival","volume":"26","author":"Hisada","year":"2019","journal-title":"Curr Opin Hematol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1158\/1535-7163.MCT-06-0154","article-title":"Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway","volume":"5","author":"Woodley-Cook","year":"2006","journal-title":"Mol Cancer Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e51650","DOI":"10.3791\/51650","article-title":"Chemotherapy-induced vascular toxicity\u2013real-time in vivo imaging of vessel impairment","volume":"2015","author":"Bar-Joseph","year":"2015","journal-title":"J Vis Exp."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e75157","DOI":"10.1371\/journal.pone.0075157","article-title":"Doxorubicin-induced vascular toxicity\u2013targeting potential pathways may reduce procoagulant activity","volume":"8","author":"Aharon","year":"2013","journal-title":"PLoS ONE."},{"key":"B28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0049-3848(94)90143-0","article-title":"Effect of various drugs on adriamycin-enhanced venous thrombosis in the rat: importance of PAF","volume":"75","author":"Bernat","year":"1994","journal-title":"Thromb Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s12265-013-9515-7","article-title":"Coagulation, protease-activated receptors, viral myocarditis","volume":"7","author":"Antoniak","year":"2014","journal-title":"J Cardiovasc Transl Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1160\/TH03-04-0203","article-title":"Evidence for functionally active protease-activated receptor-3 (PAR-3) in human vascular smooth muscle cells","volume":"90","author":"Bretschneider","year":"2003","journal-title":"Thromb Haemost."},{"key":"B31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1160\/th14-03-0243","article-title":"Tissue factor, protease activated receptors and pathologic heart remodelling","volume":"112","author":"Antoniak","year":"2014","journal-title":"Thromb Haemost."},{"key":"B32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/iub.441","article-title":"Protease-activated receptors and myocardial infarction","volume":"63","author":"Antoniak","year":"2011","journal-title":"IUBMB Life."},{"key":"B33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijcard.2017.10.019","article-title":"Evidence for functional PAR-4 thrombin receptor expression in cardiac fibroblasts and its regulation by high glucose: PAR-4 in cardiac fibroblasts","volume":"252","author":"Kleeschulte","year":"2018","journal-title":"Int J Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.yjmcc.2015.11.030","article-title":"Protease-activated receptor 4 deficiency offers cardioprotection after acute ischemia reperfusion injury","volume":"90","author":"Kolpakov","year":"2016","journal-title":"J Mol Cell Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1124\/jpet.107.133595","article-title":"Inhibiting protease-activated receptor 4 limits myocardial ischemia\/reperfusion injury in rat hearts by unmasking adenosine signaling","volume":"324","author":"Strande","year":"2008","journal-title":"J Pharmacol Exp Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1161\/CIRCULATIONAHA.119.044340","article-title":"Loss of protease-activated receptor 4 prevents inflammation resolution and predisposes the heart to cardiac rupture after myocardial infarction","volume":"142","author":"Kolpakov","year":"2020","journal-title":"Circulation."},{"key":"B37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.yjmcc.2018.08.008","article-title":"Protease-activated receptor 1 activation enhances doxorubicin-induced cardiotoxicity","volume":"122","author":"Antoniak","year":"2018","journal-title":"J Mol Cell Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jphs.2017.09.002","article-title":"A protease-activated receptor-1 antagonist protects against podocyte injury in a mouse model of nephropathy","volume":"135","author":"Guan","year":"2017","journal-title":"J Pharmacol Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1159\/000464121","article-title":"Role of protease-activated receptor 2 in regulating focal segmental glomerulosclerosis","volume":"41","author":"Wang","year":"2017","journal-title":"Cell Physiol Biochem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz","year":"1991","journal-title":"N Engl J Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","article-title":"Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia","volume":"23","author":"Lipshultz","year":"2005","journal-title":"J Clin Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e004560","DOI":"10.1161\/CIRCHEARTFAILURE.117.004560","article-title":"Left ventricular mass change after anthracycline chemotherapy","volume":"11","author":"Jordan","year":"2018","journal-title":"Circ Heart Fail."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jcmg.2018.05.012","article-title":"Anthracycline therapy is associated with cardiomyocyte atrophy and preclinical manifestations of heart disease","volume":"11","author":"Ferreira","year":"2018","journal-title":"JACC Cardiovasc Imaging."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e005234","DOI":"10.1161\/CIRCHEARTFAILURE.118.005234","article-title":"Doxorubicin exposure causes subacute cardiac atrophy dependent on the striated muscle-specific ubiquitin ligase MuRF1","volume":"12","author":"Willis","year":"2019","journal-title":"Circ Heart Fail."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1074\/jbc.RA119.011571","article-title":"Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2-mediated activation of forkhead box O1","volume":"295","author":"Xia","year":"2020","journal-title":"J Biol Chem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1161\/CIRCULATIONAHA.108.799700","article-title":"Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway","volume":"119","author":"Zhu","year":"2009","journal-title":"Circulation."},{"key":"B47","doi-asserted-by":"publisher","first-page":"13144","DOI":"10.1073\/pnas.1616168113","article-title":"VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection","volume":"113","author":"Rasanen","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1172\/JCI43008","article-title":"MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice","volume":"120","author":"Zhang","year":"2010","journal-title":"J Clin Invest."},{"key":"B49","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J Clin Invest."},{"key":"B50","doi-asserted-by":"publisher","first-page":"93358","DOI":"10.1172\/jci.insight.93358","article-title":"TRPC3-Nox2 complex mediates doxorubicin-induced myocardial atrophy","volume":"2","author":"Shimauchi","year":"2017","journal-title":"JCI Insight."},{"key":"B51","doi-asserted-by":"publisher","first-page":"9287","DOI":"10.1158\/0008-5472.CAN-10-2664","article-title":"Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated cell death pathways in doxorubicin-induced cardiotoxicity","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell Death Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"aau8866","DOI":"10.1126\/scitranslmed.aau8866","article-title":"Tissue-specific regulation of p53 by PKM2 is redox dependent and provides a therapeutic target for anthracycline-induced cardiotoxicity","volume":"11","author":"Saleme","year":"2019","journal-title":"Sci Transl Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s43018-020-0039-1","article-title":"A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy","volume":"1","author":"Amgalan","year":"2020","journal-title":"Nat Cancer."},{"key":"B56","doi-asserted-by":"publisher","first-page":"19626","DOI":"10.1073\/pnas.1904979116","article-title":"p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities","volume":"116","author":"Li","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B57","doi-asserted-by":"publisher","first-page":"146076","DOI":"10.1172\/jci.insight.146076","article-title":"TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response","volume":"6","author":"Sano","year":"2021","journal-title":"JCI Insight."},{"key":"B58","doi-asserted-by":"publisher","first-page":"44525","DOI":"10.7554\/eLife.44525","article-title":"The carboxyl-terminal sequence of bim enables bax activation and killing of unprimed cells","volume":"9","author":"Chi","year":"2020","journal-title":"Elife."},{"key":"B59","doi-asserted-by":"publisher","first-page":"19672","DOI":"10.1074\/jbc.RA118.004673","article-title":"Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy","volume":"293","author":"Xia","year":"2018","journal-title":"J Biol Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ccell.2016.11.011","article-title":"Developmental regulation of mitochondrial apoptosis by c-Myc governs age- and tissue-specific sensitivity to cancer therapeutics","volume":"31","author":"Sarosiek","year":"2017","journal-title":"Cancer Cell."},{"key":"B61","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/cvr\/cvz240","article-title":"Impaired NF-kappaB signalling underlies cyclophilin D-mediated mitochondrial permeability transition pore opening in doxorubicin cardiomyopathy","volume":"116","author":"Dhingra","year":"2020","journal-title":"Cardiovasc Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"E5537","DOI":"10.1073\/pnas.1414665111","article-title":"Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling","volume":"111","author":"Dhingra","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B64","doi-asserted-by":"publisher","first-page":"6566","DOI":"10.1073\/pnas.1201608109","article-title":"Bax regulates primary necrosis through mitochondrial dynamics","volume":"109","author":"Whelan","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e00772","DOI":"10.7554\/eLife.00772","article-title":"Bax and Bak function as the outer membrane component of the mitochondrial permeability pore in regulating necrotic cell death in mice","volume":"2","author":"Karch","year":"2013","journal-title":"Elife."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1152\/physrev.00022.2018","article-title":"Fundamental mechanisms of regulated cell death and implications for heart disease","volume":"99","author":"D.P. Del","year":"2019","journal-title":"Physiol Rev"},{"key":"B67","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbrc.2019.12.027","article-title":"Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes","volume":"523","author":"Yu","year":"2020","journal-title":"Biochem Biophys Res Commun."},{"key":"B68","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm.4017","article-title":"CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis","volume":"22","author":"Zhang","year":"2016","journal-title":"Nat Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1073\/pnas.1821022116","article-title":"Ferroptosis as a target for protection against cardiomyopathy","volume":"116","author":"Fang","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B70","doi-asserted-by":"publisher","first-page":"103456","DOI":"10.1016\/j.ebiom.2021.103456","article-title":"Loss of TRIM21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin","volume":"69","author":"Hou","year":"2021","journal-title":"EBioMedicine."},{"key":"B71","doi-asserted-by":"publisher","first-page":"132747","DOI":"10.1172\/jci.insight.132747","article-title":"Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity","volume":"5","author":"Tadokoro","year":"2020","journal-title":"JCI Insight."},{"key":"B72","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41419-020-02948-2","article-title":"Acyl-CoA thioesterase 1 prevents cardiomyocytes from Doxorubicin-induced ferroptosis via shaping the lipid composition","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.yjmcc.2021.08.006","article-title":"MITOL\/MARCH5 determines the susceptibility of cardiomyocytes to doxorubicin-induced ferroptosis by regulating GSH homeostasis","volume":"161","author":"Kitakata","year":"2021","journal-title":"J Mol Cell Cardiol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.yjmcc.2019.08.009","article-title":"Doxorubicin induces cardiomyocyte pyroptosis via the TINCR-mediated posttranscriptional stabilization of NLR family pyrin domain containing 3","volume":"136","author":"Meng","year":"2019","journal-title":"J Mol Cell Cardiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"H460","DOI":"10.1152\/ajpheart.00056.2019","article-title":"Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis","volume":"317","author":"Tavakoli Dargani","year":"2019","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"117186","DOI":"10.1016\/j.lfs.2019.117186","article-title":"Bnip3 mediates doxorubicin-induced cardiomyocyte pyroptosis via caspase-3\/GSDME","volume":"242","author":"Zheng","year":"2020","journal-title":"Life Sci."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.817977\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:20:40Z","timestamp":1642378840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.817977\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":76,"alternative-id":["10.3389\/fcvm.2021.817977"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.817977","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"article-number":"817977"}}